*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
The Correlation of TGF-ß Level and GARP Gene Expression in Iraqi Patients with Rheumatoid Arthritis Treated By Biological and Chemo-Therapy

Author: SHAWQ RAAFAT MOHAMMED, ZAINAB THAMER SHOWAIT AL-ASADY, MOHAMMED MAHDI JAWAD, MOHAMMED H. ALOSAMI
Abstract: GARP is a leucine rich repeat family member that play role in mediating the surface expression of TGF-ß in regulatory T cells, TGF-ß is one of anti-inflammatory cytokines that plays role in inhibits T effector proliferation and differentiation in autoimmune disease. The study aims to estimate the level of TGF-ß1 and gene expression of LRRC32 gene (GARP) in Iraqi patients with Rheumatoid arthritis treated by biological and chemotherapy. lood samples were collected from 30 patients diagnosed with Rheumatoid arthritis (RA) and 24 healthy donors as control group to measure the level of TGF-ß1 by ELISA and the gene expression of LRRC32 (GARP gene) by RT-qPCR technique. Rheumatoid arthritis patients showed a significant decrease in the TGF-ß1 level in the serum of RA patients that treated with biological therapy compared to other type of treatments as well as to control group. A significant increase was detected in the folding of gene expression of LRRC32 gene in RA patients treated with biological therapy and others that treated with biological and chemotherapy compared to control group. Although, high effectiveness of Treg cells in patients with RA under biological and chemotherapy through the increase the folding of LRRC32 gene expression, the results of current study showed there was decrease in the TGF-ß level in patients with RA under biological therapy because the inhibition of pro-inflammatory factors, including TNF-a that affects the efficacy of the effector cells, including Th and Treg that may reflect on TGF-ß level production from Treg.
Keyword: rheumatoid arthritis, LRRC32 gene, GARP, TGF-ß1, Biological therapy.
DOI: https://doi.org/10.31838/ijpr/2020.SP1.240
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free